Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP
NCT02049866 is a phase 2 interventional trial sponsored by Elizabeth Shane. As of 21 Nov 2026, it is completed. It studies Denosumab in Adult Idiopathic Generalized Osteoporosis. The registry lists an enrollment of 33 participants at 2 sites in 1 country. The registry lists a start date of 19 Nov 2014 and a primary completion date of 31 Mar 2020.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT02049866 |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | Elizabeth Shane |
| Enrollment | 33 |
| Registered sites | 2 |
| Countries | 1 |
| Conditions | Adult Idiopathic Generalized Osteoporosis |
| Drugs | Denosumab |
| Start | 19 Nov 2014 |
| Primary completion | 31 Mar 2020 |
| Study completion | 23 Dec 2021 |
| Last update posted | 12 Dec 2022 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Adi Cohen, MD
Columbia University
Principal Investigator - Elizabeth Shane, MD
Columbia University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Creighton University
Omaha
- Columbia University Medical Center
New York
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT02049866
Each answer restates registry values shown on this page.
What is NCT02049866?
NCT02049866 is a phase 2 interventional trial sponsored by Elizabeth Shane. It studies Denosumab in Adult Idiopathic Generalized Osteoporosis.
Who leads NCT02049866?
The registry names Adi Cohen, MD (principal investigator, Columbia University) and Elizabeth Shane, MD (principal investigator, Columbia University) as overall officials.
Where does NCT02049866 run?
The registry lists 2 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT02049866 study?
The registered drug and biological interventions are Denosumab.
When did NCT02049866 end?
The registry lists a primary completion date of 31 Mar 2020 and a study completion date of 23 Dec 2021. The sponsor last updated the record on 12 Dec 2022.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.